

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/231275 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) *A61K 45/06* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)
A61K 31/565 (2006.01)

(21) International Application Number:

PCT/EP2024/062253

(22) International Filing Date:

03 May 2024 (03.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/500,348 05 May 2023 (05.05.2023) US
63/568,170 21 March 2024 (21.03.2024) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **BARRY, Simon**; AstraZeneca UK Limited,
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge, Cambridgeshire CB2 0AA (GB). **FOXLEY,
Andrew**; AstraZeneca UK Limited, 1 Francis Crick Ave-
nue, Cambridge Biomedical Campus, Cambridge, Cam-
bridgeshire CB2 0AA (GB). **MCDONOUGH, Amy**; As-
traZeneca UK Limited, 1 Francis Crick Avenue, Cam-
bridge Biomedical Campus, Cambridge, Cambridgeshire
CB2 0AA (GB). **DE BRUIN, Elza**; AstraZeneca UK

Limited, 1 Francis Crick Avenue, Cambridge Biomed-
ical Campus, Cambridge, Cambridgeshire CB2 0AA (GB).
SCHIAVON, Gaia; AstraZeneca UK Limited, 1 Fran-
cis Crick Avenue, Cambridge Biomedical Campus, Cam-
bridge, Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Association 813, Eastbrook House, Shaftesbury Road,
CAMBRIDGE, Cambridgeshire CB2 8BF (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMBINATION OF CAPIVASERTIB, A CDK4/6 INHIBITOR AND FULVESTRANT FOR USE IN THE TREATMENT OF BREAST CANCER




Fig. 1

(57) Abstract: The specification relates to therapeutic combinations of capivasertib, a CDK4/6 inhibitor (such as palbociclib, ribociclib or abemaciclib) and fulvestrant that are useful for treating breast cancer, and to methods of treating breast cancer patients with combinations of capivasertib, a CDK4/6 inhibitor (such as palbociclib, ribociclib or abemaciclib) and fulvestrant.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*